【佳学基因检测】ANRIL 的高表达与癌症患者的不良预后相关：一项荟萃分析

肿瘤基因检测回扣机会

参加学术会议时成人肿瘤与儿童肿瘤基因检测序列的异同点《肿瘤治疗效果与基因检测结果的相关性》《Medicine (Baltimore)》在. 2022 Sep 9;101(36):e30531.发表了一篇题目为《ANRIL 的高表达与癌症患者的不良预后相关：一项荟萃分析》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Yun Liu, Linqi Zhu, Wenjun Zhao, Yong Zhou, Shihe Shao 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

背景：ANRIL，也称为CDKN2B反义RNA 1，是心血管疾病的重要遗传易感位点，与多种病理相关，包括多种人类癌症。目的：分析ANRIL与癌症患者临床结局或预后的关系。荟萃分析。方法：从 3 个数据库（Pubmed、Cochrane Library 和 EMBASE）的 23 项研究中选择 1708 名癌症患者。结果：固定效应模型表明，ANRIL 的高表达与较差的表达明显相关。总生存期 (总生存期)（风险比 [HR] = 1.77，95% 置信区间 [CI] = 1.57-2.00，P < .00001）；随机效应模型显示无病生存期 (无病生存期) 较差 (HR = 1.86, 95% CI: 1.46-2.37, P < .00001)。高水平的 ANRIL 表达也与肿瘤大小（小与大，优势比 [OR] = 0.57，95% CI：0.39-0.83，P = .003）、TNM 分期（I + II vs III + IV ; OR = 0.40, 95% CI: 0.24-0.69, P = .0008) 和淋巴结转移 (LNM) (Yes vs No, OR = 3.66, 95% CI: 1.46-9.17, P = .006)。 ANRIL 与组织学分化没有显着相关性，与差和中等 + 好相比； OR 值为 0.74，95% CI：0.26-2.12，P = .58。此外，有证据表明，高水平的 ANRIL 与人类癌症类型、随访时间和样本量呈正相关。结论：该荟萃分析表明，ANRIL 可能是预测癌症患者预后不良的有价值的生物标志物。

肿瘤发生与复发转移国际数据库描述：

Background: ANRIL, also called CDKN2B antisense RNA 1, is an important genetic susceptibility locus for cardiovascular diseases and associated with numerous pathologies, including several human cancers.Objective: The relationship between ANRIL and the clinical outcome or prognosis of cancer patients was analyzed in this meta-analysis.Methods: One thousand seven hundred eight cancer patients were selected in 23 studies from 3 databases (Pubmed, Cochrane Library, and EMBASE).Results: A fixed-effects model indicated that the high expression of ANRIL is obviously linked to poor overall survival (OS) (Hazard ratio [HR] = 1.77, 95% confidence interval [CI] = 1.57-2.00, P < .00001); the random-effects model revealed poor disease-free survival (DFS) (HR = 1.86, 95% CI: 1.46-2.37, P < .00001). A high level of ANRIL expression was also associated with the tumor size (small vs large, odds ratio [OR] = 0.57, 95% CI: 0.39-0.83, P = .003), TNM stage (I + II vs III + IV; OR = 0.40, 95% CI: 0.24-0.69, P = .0008), and lymph node metastasis (LNM) (Yes vs No, OR = 3.66, 95% CI: 1.46-9.17, P = .006). ANRIL was not related significantly to histologic differentiation compared to poor with moderate + well; the OR value is 0.74, 95% CI: 0.26-2.12, P = .58. In addition, evidence suggested that a high level of ANRIL was positively associated with human cancer type, follow-up time, and sample size.Conclusion: This meta-analysis demonstrated that ANRIL may be a valuable biomarker for predicting poor prognosis in cancer patients.